BeOne Medicines Reports Strong Q3 2026 Results and Raises Full-Year Revenue Guidance
BeOne Medicines (ONC) delivered robust third-quarter 2026 financial results, headlined by total revenue of $1.89 billion, a 34% increase year-over-year. Growth was primarily driven by the global hematology portfolio, with BRUKINSA sales reaching $1.41 billion and U.S. BRUKINSA sales surpassing the $1 billion quarterly milestone for the first time. The company also saw significant gains from TEVIMBRA and its Amgen in-license portfolio. Profitability showed substantial improvement as GAAP operating income surged 157% to $419 million, reflecting enhanced business scalability. Following these strong results, BeOne Medicines raised its full-year 2026 revenue guidance to a range of $6.9 billion to $7.0 billion and increased its GAAP operating income outlook by $200 million. While the company faces potential future revenue pressure from biosimilar competition for certain brands, its current cash position of $5.87 billion provides significant flexibility for pipeline development.
Topics: Free Cash Flow Hematology Operating Income Product Sales Revenue Growth